



UNIVERSITY
OF OSTRAVA



FAKULTNÍ
NEMOCNICE
OSTRAVA

Microfluidics in organoid systems

Juli R Bago




Blood Cancer
Research Group


CELL THERAPY TEAM

BCRG


Genomic and bioinformatics team



Cell and molecular biology team



Cell therapy team




CELL THERAPY TEAM

Cell based-immunotherapy: CAR-T cells



CELL THERAPY TEAM

Cell based-immunotherapy: NK cells




CART-CELL THERAPY

Expensive=400K \$. Autologous to avoid GvHD

CAR T cells exert immune reaction towards a specific tumor antigen.

CELL THERAPY TEAM

Cell based-immunotherapy: NK cells



Mensali N, et al. NK cells specifically TCR-dressed to kill cancer cells. 2019. EBioMedicine

CELL THERAPY TEAM

Cell based-immunotherapy: Validation

IN VIVO




Mouse models of hematological cancer

- Ethical issue
- Differences in physiology and genetics between animals of experimentation and humans.

CELL THERAPY TEAM

Cell based-immunotherapy: Validation


IN VITRO

Culture model	Advantages	Disadvantages
2D cell culture 	Methodology well established Simplicity to work with cell monolayer	Static conditions Uniform concentration of nutrients and drugs Lack of 3D environment Large reagent volumes

Valente et al. Microfluidic technologies for anticancer drug studies. 2017. Drug discovery today.

CELL THERAPY TEAM

Cell based-immunotherapy: Validation





www.tebu-bio.com/blog/

CELL THERAPY TEAM

Cell based-immunotherapy: Validation

IN VITRO

MiniBrains




Lancaster, M. A. et al. 2013. Nature.

CELL THERAPY TEAM

Cell based-immunotherapy: Validation

IN VITRO

Mini Hearts




Cell Applications inc

CELL THERAPY TEAM

Cell based-immunotherapy: Validation



IN VITRO
Vascularization



CELL THERAPY TEAM

Cell based-immunotherapy: Validation

IN VITRO


Culture model	Advantages	Disadvantages
<p>2D cell culture</p> 	<p>Methodology well established Simplicity to work with cell monolayer</p>	<p>Static conditions Uniform concentration of nutrients and drugs Lack of 3D environment Large reagent volumes</p>
<p>3D cell culture</p> 	<p>Cell-cell and cell-ECM interactions Sensitivity to cytotoxic agents similar to <i>in vivo</i></p>	<p>Failure to produce dynamic environment Lack of fluid flow perfusion</p>

Valente et al. Microfluidic technologies for anticancer drug studies. 2017. Drug discovery today.

CELL THERAPY TEAM

Cell based-immunotherapy: Validation


IN VITRO Vascularization



Sekine et al. In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. 2013. Nat Commun.

CELL THERAPY TEAM

Cell based-immunotherapy: Validation



Samuel Constant et al. *Advanced Human In vitro Models for the Discovery and Development of Lung Cancer Therapies*. 2015.

CELL THERAPY TEAM

THANK YOU SO MUCH

